News & Updates
Filter by Specialty:
COVID-19 vaccines weaker in liver transplant recipients, CLD patients
Vaccines against the coronavirus disease 2019 (COVID-19) induce weaker and more transient immune responses in liver transplant recipients, those with cirrhosis, or those with chronic liver disease (CLD), according to a study presented at The Liver Meeting Digital Experience 2021 by the American Association for the Study of Liver Diseases (AASLD 2021).
COVID-19 vaccines weaker in liver transplant recipients, CLD patients
19 Nov 2021No trade-off between bleeding and ischaemic risk with abbreviated DAPT
Stopping dual antiplatelet therapy (DAPT) after 1 month appeared safe in high-bleeding risk (HBR) patients with acute myocardial infarction (MI) who were implanted with a newer coronary stent, a prespecified subanalysis of the MASTER DAPT* trial has shown.
No trade-off between bleeding and ischaemic risk with abbreviated DAPT
19 Nov 2021Liver injury persists in patients with vaccine breakthrough COVID-19
Liver injury is not uncommon among patients with vaccine breakthrough COVID-19, indicating the importance of monitoring liver injury enzymes, according to a study presented at The Liver Meeting 2021 by the American Association for the Study of Liver Diseases (AASLD 2021).
Liver injury persists in patients with vaccine breakthrough COVID-19
18 Nov 2021Resveratrol supplements confer minimal benefits in T2D, MetS, NAFLD
Supplementation with resveratrol does not appear to provide much benefit in the management of cardiometabolic risk factors in patients with type 2 diabetes (T2D), metabolic syndrome (MetS), and nonalcoholic fatty liver disease (NAFLD), suggests a study.